Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson's disease

BACKGROUND: In Parkinson's disease (PD), the motor presentation characterised by postural instability/gait difficulties (PIGD) heralds accelerated motor, functional and cognitive decline, as compared with the more benign tremor-dominant (TD) variant. This makes the PIGD complex an attractive target for the discovery of prognostic biomarkers in PD. OBJECTIVE: To explore in vivo whether variability in brain amyloid-beta (Abeta) metabolism affects the initial motor presentation in PD. METHODS: We quantified cerebrospinal fluid (CSF) concentrations and ratios of Abeta42, Abeta40 and Abeta38 using a triplex immunoassay in 99 patients with de novo PD with the PIGD phenotype (n=39) or the TD phenotype (n=60). All patients underwent standardised assessments of motor and neuropsychological function and cerebral MRI. 46 age-matched normal controls served as external reference. RESULTS: Patients with PD with the PIGD phenotype had significantly reduced CSF Abeta42, Abeta38, Abeta42/40 and Abeta38/40 levels compared with patients with the TD phenotype and controls. CSF marker levels in patients with PD-TD did not differ from those in controls. Multivariate regression models demonstrated significant associations of CSF Abeta markers with severity of PIGD and lower limb bradykinesia in patients with PD, independently from age, MRI white matter hyperintensities and cognition. No associations were found between CSF markers and other motor features. CONCLUSIONS: Motor heterogeneity in de novo PD independently relates to CSF Abeta markers, with low levels found in patients with the PIGD presentation. This suggests that disturbed Abeta metabolism has an effect on PD beyond cognition and may contribute to the variable rate of motor and functional decline in PD